Business Context and Reporting Period
This Form 8-K was filed by Avalo Therapeutics, Inc. on September 26, 2023, reporting events occurring on September 22, 2023. The filing details the repayment of a material debt obligation and provides updates on the company's liquidity position and Nasdaq listing status.
Key Financial Metrics
- Debt Repayment: The Company repaid all outstanding principal, interest, and final payment fees on its Venture Loan and Security Agreement in the aggregate amount of $14,251,320.
- Liquidity: Following the debt payoff, the Company estimated approximately $3.7 million in cash and cash equivalents as of September 25, 2023. This figure is preliminary and unaudited.
- Capital Raised: Under an At-The-Market (ATM) Sales Agreement with Oppenheimer & Co. Inc., the Company raised approximately $12.9 million in net proceeds between September 11 and September 21, 2023, via the sale of 84,220,464 shares. An additional 20,000,000 shares were sold for approximately $2.6 million in net proceeds subsequent to September 21, pending settlement.
- Share Count: As of September 25, 2023, the Company had 147,091,027 shares outstanding (excluding the post-September 21 sales).
Material Changes
- Debt Elimination: The repayment satisfied all obligations under the Note and Note Amendment, extinguishing the security interest in the Company's assets and negating the requirement to maintain a $3,000,000 Cash Deposit.
- Resolution of Default: The payoff resolved the "Existing Default" previously asserted by lenders on July 20, 2023, which had triggered forbearance agreements.
- Stock Price Decline: The Company's stock price closed at $0.10 or less for ten consecutive trading days ending September 11, 2023, triggering a Nasdaq Staff Delisting Determination.
Outlook, Risks, and Contingencies
- Nasdaq Delisting Risk: The Company received notice of a Staff Delisting Determination due to failure to meet the minimum bid price ($1.00) and Market Value of Listed Securities ($35 million) requirements. The Company has timely requested an appeal to a Hearings Panel.
- Compliance Deadline: The Company has until February 5, 2024, to regain compliance with Nasdaq listing rules, though the immediate delisting determination requires a successful appeal.
- Financial Uncertainty: The reported cash balance of $3.7 million is preliminary and subject to change upon completion of financial statement closing procedures and audits.
Investor Verification Checklist
- Verify the final audited cash balance as of September 30, 2023, to confirm the preliminary $3.7 million estimate.
- Monitor the status of the appeal to the Nasdaq Hearings Panel regarding the delisting determination.
- Review the settlement of the 20,000,000 shares sold after September 21, 2023, to confirm the actual cash inflow and updated share count.
- Assess the Company's runway given the $3.7 million cash position and ongoing operational burn rate.